Efficacy and cost of etanercept in long-term XXXX : Rational use in clinical practice.

@entity1 @entity1569
INTRODUCTION: The advent of the biological therapies has led health expenditure in dermatology units. This study aims to evaluate, in our regular clinical practice, the patterns of use of etanercept and its influence on efficacy and safety outcomes, as well as the real costs associated with continuous and intermittent treatment regimens. METHODS: Observational, retrospective, non-interventionist, and multicenter study to analyze the experience of the treatment with etanercept in the management of moderate-to-severe @entity1569 , given according to the daily clinical practice of the Dermatology Departments of the Complejo Hospitalario de Ja  n and the Hospital Universitario Virgen del Roc  o (Seville). RESULTS: 83.3% (n   =   45) of the 54 @entity1 included in our study received the continuous regimen of Etanercept, whereas 16.7% (n   =   9) were given the intermittent regimen. 94.4% (n   =   51) of the @entity1 studied began the Etanercept treatment at a dose of 50   mg/week. The mean @entity1 /year cost of the study population is    11   298.80 (95%CI    10   551.40-   12   046.20). Breaking down the first and the second year of treatment by regimen, in the continuous regimen the mean cost would be    12   294.15 and    12   327.05 in the first and the second year, respectively, and    10   302.07 and    4986.51 in the intermittent regimen. DISCUSSION: Etanercept is a biologic that had demonstrated its versatility over the years and permits the individualization of treatment in our @entity1 , thus having a direct impact on drug-related costs. This is well demonstrated in our series, where 94.4% of our @entity1 begin with the dose of 50   mg/d. Our study yields relatively higher figures in @entity1 on continuous therapy, with 77.1% of them maintaining PASI75 at week 24. CONCLUSIONS: We present our experience in regular clinical practice with etanercept, showing it to be an effective, safe, and versatile drug that permits @entity1 -tailored treatment, delivering a frankly satisfactory control of our @entity1569 @entity1 .
